Litigation Details for UCB, Inc. v. Mylan Technologies Inc. (D. Vt. 2022)
✉ Email this page to a colleague
UCB, Inc. v. Mylan Technologies Inc. (D. Vt. 2022)
| Docket | ⤷ Sign Up | Date Filed | 2022-12-12 |
| Court | District Court, D. Vermont | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Christina Clair Reiss |
| Jury Demand | None | Referred To | |
| Patents | 10,130,589; 10,350,174; 6,699,498; 6,884,434; 7,413,747; 8,246,979; 8,246,980; 8,617,591; 9,925,150 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in UCB, Inc. v. Mylan Technologies Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for UCB, Inc. v. Mylan Technologies Inc. (D. Vt. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2022-12-12 | 1 | Exhibit A | Tarnada ......... ............... 600/347 6,699,498 Bl 3/2004 Millier ....... .... ... …States Patent (IO) Patent No.: … appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below… appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below… COMPLAINT for Patent Infringement against Mylan Technologies Inc. filed by UCB, Inc., UCB Pharma | External link to document |
| 2024-03-08 | 176 | other patents connected with Neupro®: U.S. Patent Nos. 10,130,589 (the "'589 Patent") … and '980 Patents, as well U.S. Patent Nos. 8,617,591 (the '"591 Patent") and 9,925,150…x27; 150 patents, or of any other patent, including by not limited to U.S. Patent Nos. 10,130,589…non- infringement of U.S. Patent Nos. 8,246,979 (the "'979 Patent") and 8,246,980 (the … has six patents associated with it in the FDA's Orange Book, including the four patents at issue | External link to document | |
| 2023-03-06 | 31 | Answer to Counterclaim | the ’979 and ’980 patents, as well as the ’591 patent and U.S. Patent Nos. 6,884,434 and 7,413,747. No…980, ’589 and ’174 patents, as well as U.S. Patent Nos. 8,617,591 (“the ’591 patent”) and 9,925,150 (“…to U.S. Patent Nos. 7,413,747 (“the ’747 Patent”); 8,246,979 (“the ’979 Patent”); 8,246,980… Patent”); and 8,617,591 (“the ’591 Patent”) (collectively the “Covenant Patents”) are…Pharma is the assignee of the ’979 patent. A copy of the ’979 patent was attached to Counterclaim Defendants | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
